Skip to main navigation Skip to search Skip to main content

Antiarrhythmic drugs-clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP)

  • Gheorghe Andrei Dan*
  • , Antoni Martinez-Rubio
  • , Keld Kjeldsen
  • , ESC Scientific Document Group
  • *Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

Original languageEnglish
Pages (from-to)731-732
Number of pages2
JournalEuropace
Volume20
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Funding

1Colentina University Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania; 2University Hospital of Sabadell (University Autonoma of Barcelona), Plac¸a Cívica, Campus de la UAB, Barcelona, Spain; 3Oslo University Hospital Ullevål, Norway; 4Institute of Clinical Sciences, University of Oslo, Søsterhjemmet, Oslo, Norway; 5Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy; 6Universitaetsmedizin Mannheim, Medizinische Klinik, Mannheim, Germany; 7Department of Medical Sciences, University of Turin, Citta’ della Salute e della Scienza Hospital, Turin, Italy; 8Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 9Department of Cardiology, Eskisehir Osmangazi University, Büyükdere Mahallesi, Odunpazarı/Eskis¸ehir, Turkey; 10Molecular and Clinical Sciences Research Institute, St. George’s, University of London, London, UK; 11Copenhagen University Hospital (Holbæk Hospital), Holbæk, Institute for Clinical Medicine, Copenhagen University, Copenhagen, Denmark; 12Department of Health Science and Technology, Aalborg University, Aalborg, Denmark; 13Institute of Cardiovascular Sciences, University of Birmingham, Centre For Cardiovascular Sciences, City Hospital, Birmingham, UK; 14Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark; 15Heart and Vascular Center, Semmelweis University, Budapest, Hungary; 16Saiseikai Akumamoto Hospital, Kumamoto, Japan; 17Department of Medicine, Duke Clinical Research Institute, Durham, USA; 18School of Medicine, Belgrade University; Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia; 19Aarhus University Hospital, Klinisk Farmakologisk Enhed, Aalborg, Denmark; 20Department of Pharmacology, School of Medicine, Universidad Complutense Madrid, Madrid, Spain; 21Department of Medicine - Cardiology, Klinikum Ludwigsburg, Ludwigsburg, Germany; 22Department of Cardiology, University Hospital Basel, Basel, Switzerland; 23Medizinische Klinik I-Kardiologie, Angiologie, Pneumologie, Wiesbaden, Germany; 24Barts Heart Centre, Trustee Arrhythmia Alliance and Atrial Fibrillation Association, London, UK; 25Department of Cardiology, University Hospital Centre Sestre milosrdnice, Croatia; 26Cardiology Department, Olv Aalst, Belgium; 27Uniwersytet Medyczny w Łodzi, Kierownik Kliniki Kardiologii

Keywords

  • Antiarrhythmic drugs
  • Arrhythmias
  • Atrial fibrillation
  • Bradycardia
  • EHRA consensus document
  • Extrasystoles
  • Pre-excitation
  • Proarrhythmias
  • Sudden cardiac death
  • Supraventricular arrhythmias
  • Ventricular tachycardia

Cite this